KR101378260B1 - 세로토닌 및 노르에피네프린 재흡수 억제제 - Google Patents

세로토닌 및 노르에피네프린 재흡수 억제제 Download PDF

Info

Publication number
KR101378260B1
KR101378260B1 KR1020117023570A KR20117023570A KR101378260B1 KR 101378260 B1 KR101378260 B1 KR 101378260B1 KR 1020117023570 A KR1020117023570 A KR 1020117023570A KR 20117023570 A KR20117023570 A KR 20117023570A KR 101378260 B1 KR101378260 B1 KR 101378260B1
Authority
KR
South Korea
Prior art keywords
methyl
pyrrolidine
mmol
chloro
butyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020117023570A
Other languages
English (en)
Korean (ko)
Other versions
KR20110123287A (ko
Inventor
니콜라스 자크스 프랑코이스 드레이푸스
샌드라 앤 필라
아네트 마가레타 요한슨
티어리 제이. 마스?린
지케쉬 아빈드 샤
에릭 조지 트로믹자크
매그너스 빌헬름 월터
Original Assignee
일라이 릴리 앤드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 일라이 릴리 앤드 캄파니 filed Critical 일라이 릴리 앤드 캄파니
Publication of KR20110123287A publication Critical patent/KR20110123287A/ko
Application granted granted Critical
Publication of KR101378260B1 publication Critical patent/KR101378260B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020117023570A 2009-04-09 2010-04-06 세로토닌 및 노르에피네프린 재흡수 억제제 Expired - Fee Related KR101378260B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16807909P 2009-04-09 2009-04-09
US61/168,079 2009-04-09
PCT/US2010/030038 WO2010117979A2 (en) 2009-04-09 2010-04-06 Serotonin and norepinephrine reuptake inhibitor

Publications (2)

Publication Number Publication Date
KR20110123287A KR20110123287A (ko) 2011-11-14
KR101378260B1 true KR101378260B1 (ko) 2014-03-27

Family

ID=42698378

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020117023570A Expired - Fee Related KR101378260B1 (ko) 2009-04-09 2010-04-06 세로토닌 및 노르에피네프린 재흡수 억제제

Country Status (14)

Country Link
US (1) US8173821B2 (https=)
EP (1) EP2417124B1 (https=)
JP (1) JP2012523416A (https=)
KR (1) KR101378260B1 (https=)
CN (1) CN102388036A (https=)
AR (1) AR075988A1 (https=)
AU (1) AU2010234610B2 (https=)
BR (1) BRPI1014382A2 (https=)
CA (1) CA2758251C (https=)
EA (1) EA201171230A1 (https=)
ES (1) ES2446644T3 (https=)
MX (1) MX2011010658A (https=)
TW (1) TW201103908A (https=)
WO (1) WO2010117979A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010011811A2 (en) 2008-07-24 2010-01-28 Theravance, Inc. 3-(phenoxyphenylmethyl)pyrrolidine compounds
WO2010120910A1 (en) * 2009-04-15 2010-10-21 Theravance, Inc. 3-(phenoxypyrrolidin-3-yl-methyl)heteroaryl, 3-(phenylpyrrolidin-3-ylmethoxy)heteroaryl, and 3-(heteroarylpyrrolidin-3-ylmethoxy)heteroaryl compounds
AU2010273645B2 (en) * 2009-07-13 2014-12-04 Theravance Biopharma R&D Ip, Llc 3-phenoxymethylpyrrolidine compounds
US8273786B2 (en) 2009-07-21 2012-09-25 Theravance, Inc. 3-phenoxymethylpyrrolidine compounds
US8471040B2 (en) 2010-10-11 2013-06-25 Theravance, Inc. Serotonin reuptake inhibitors
US8501964B2 (en) 2010-12-03 2013-08-06 Theravance, Inc. Serotonin reuptake inhibitors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020151712A1 (en) 1999-09-14 2002-10-17 Nan-Horng Lin 3-pyrrolidinyloxy-3'-pyridyl ether compounds useful for controlling chemical synaptic transmission

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL1004346C2 (nl) 1996-10-23 1998-04-24 Dsm Nv Werkwijze voor het scheiden van een mengsel van enantiomeren in een geschikt oplosmiddel.
CA2698384C (en) * 1996-12-10 2012-05-01 Abbott Laboratories 3-pyridyl enantiomers and their use as analgesics
DK1047690T3 (da) 1997-12-19 2004-07-05 Abbott Lab Heterocykliske ether- og thioetherforbindelser, som er anvendelige til regulering af kemisk, synaptisk overförsel
JP2003529547A (ja) 1999-09-14 2003-10-07 アボット・ラボラトリーズ 化学シナプス伝達のコントロールに有効な３−ピロリジニルオキシ−３’−ピリジルエーテル化合物
BRPI0510453A (pt) 2004-04-30 2007-10-30 Warner Lambert Co composto substituìdos com morfolina para o tratamento de distúrbios do sistema nervoso central
EP2066630A1 (en) * 2006-08-23 2009-06-10 Pfizer Products Incorporated Piperidine derivatives
ATE528300T1 (de) 2006-12-06 2011-10-15 Glaxosmithkline Llc Bizyklische verbindungen und ihre verwendung als antidiabetika
WO2010011811A2 (en) 2008-07-24 2010-01-28 Theravance, Inc. 3-(phenoxyphenylmethyl)pyrrolidine compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020151712A1 (en) 1999-09-14 2002-10-17 Nan-Horng Lin 3-pyrrolidinyloxy-3'-pyridyl ether compounds useful for controlling chemical synaptic transmission

Also Published As

Publication number Publication date
CN102388036A (zh) 2012-03-21
MX2011010658A (es) 2011-10-21
CA2758251A1 (en) 2010-10-14
AU2010234610B2 (en) 2013-04-18
US20100261762A1 (en) 2010-10-14
TW201103908A (en) 2011-02-01
WO2010117979A3 (en) 2011-02-17
BRPI1014382A2 (pt) 2016-04-05
US8173821B2 (en) 2012-05-08
ES2446644T3 (es) 2014-03-10
EP2417124A2 (en) 2012-02-15
EP2417124B1 (en) 2013-12-18
AR075988A1 (es) 2011-05-11
CA2758251C (en) 2013-08-06
EA201171230A1 (ru) 2012-03-30
JP2012523416A (ja) 2012-10-04
AU2010234610A1 (en) 2011-10-06
KR20110123287A (ko) 2011-11-14
WO2010117979A2 (en) 2010-10-14

Similar Documents

Publication Publication Date Title
JP4488891B2 (ja) Ｎ−［フェニル（ピペリジン−２−イル）メチル］ベンズアミド誘導体、その製造法、およびその治療用途
JP5377503B2 (ja) 置換されたｎ−フェニル−ビピロリジンカルボキサミド及びその治療上の使用
CN110234638B (zh) 杂芳基苯氧基苯甲酰胺kappa阿片类配体
KR20040103973A (ko) Ｎ-[페닐(피페리딘-2-일)메틸]벤즈아미드의 유도체, 그의제조 방법 및 치료법에서의 그의 용도
KR101378260B1 (ko) 세로토닌 및 노르에피네프린 재흡수 억제제
CN102753540B (zh) α4β2神经元烟碱型乙酰胆碱受体的配体
WO2006046575A1 (ja) シンナミド化合物の非晶質体
WO2015079692A1 (ja) ウレア誘導体、またはその薬理学的に許容される塩
TW202112768A (zh) 二取代吡唑化合物
KR101682889B1 (ko) 치환된 테트라하이드로피란 스피로 피롤리디논 및 피페리디논, 이의 제조방법 및 이의 치료 용도
JP5829689B2 (ja) ピロリジン−３−イル酢酸誘導体
CZ342397A3 (cs) Piperazinové deriváty jako antagonisté neurokininu
CA3061762C (en) 3-methyl-pyrrolidine-2,5-dione derivatives useful as cgrp receptor antagonists
JP6941235B2 (ja) イミダゾピリジン誘導体及び薬物としてのその使用
JP2009523747A (ja) α７ニコチン性アセチルコリン受容体のモジュレーターおよびその治療上の使用
JP2013529198A (ja) 置換されたｎ−ヘテロシクロアルキルビピロリジニルフェニルアミド誘導体、その製造及び治療上の使用
KR20150090769A (ko) 아릴옥시 아제티딘 화합물, 및 이를 포함하는 약학 조성물
HK40014240A (en) Heteroarylphenoxy benzamide kappa opioid ligands
HK40014240B (zh) 杂芳基苯氧基苯甲酰胺kappa阿片类配体
HK1146053B (en) Substituted n-phenyl-bipyrrolidine carboxamides and therapeutic use thereof

Legal Events

Date Code Title Description
A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20170320

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20170320